

Estudio Propio: **EXPERTO EN TRICOLOGÍA MÉDICO-ESTÉTICA AVANZADA**

Código Plan de Estudios: **EÑ13**

Año Académico: **2019-2020**

<b>ESTRUCTURA GENERAL DEL PLAN DE ESTUDIOS:</b>							
CURSO	Obligatorios		Optativos		Prácticas Externas	Memoria/ Proyecto	Créditos
	Créditos	Nº Asignaturas	Créditos	Nº Asignaturas	Créditos	Créditos	
1º	19	2				10	29
2º							
3º							
<b>ECTS TOTALES</b>	<b>19</b>	<b>2</b>				<b>10</b>	<b>29</b>

<b>PROGRAMA TEMÁTICO:</b>				
<b>ASIGNATURAS OBLIGATORIAS</b>				
Código Asignatura	Curso	Denominación	Carácter OB/OP	Créditos
705508	1	TRICOLOGÍA MÉDICO-ESTÉTICA AVANZADA: ACTUALIZACIÓN PRÁCTICA	OB	12
705509	1	PRÁCTICA CLÍNICA EN TRICOLOGÍA MÉDICO-ESTÉTICA	OB	7
<b>MEMORIA /PROYECTO</b>				
Código Asignatura	Curso	Denominación	Carácter OB/OP	Créditos
705510	1	TRABAJO DE INVESTIGACIÓN DE FIN DE CURSO	OB	10

Carácter: OB - Obligatoria; OP – Optativa

**GUÍA DOCENTE**

Año académico	2019-2020	
Estudio	Experto en Tricología médico-estética avanzada (EÑ13)	
Nombre de la asignatura	TRICOLOGÍA MÉDICO-ESTÉTICA AVANZADA: ACTUALIZACIÓN PRÁCTICA	
Carácter (Obligatoria/Optativa)	OB	
Créditos (1 ECTS=25 horas)	12	
Modalidad (elegir una opción)	<input type="checkbox"/>	Presencial
	<input type="checkbox"/>	Semipresencial
	<input checked="" type="checkbox"/>	On-line
Profesor responsable	David Saceda Corralo	
Idioma en el que se imparte	Español	

**DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)**

Número de horas presenciales/on-line asistencia profesor	84
Número de horas de trabajo personal del estudiante	216
Total horas	300

**CONTENIDOS (Temario)**

- INTRODUCCIÓN Y EXPLORACIÓN EN TRICOLOGÍA.
- a. Anamnesis y exploración clínica
  - b. Tricoscopia básica
  - c. Tricoscopia avanzada en alopecias cicatriciales
  - d. Tricograma, trichoscan y otros métodos diagnósticos
2. CLASIFICACIÓN DE ALOPECIAS
- a. Alopecias no cicatriciales
  - b. Alopecias cicatriciales
3. TERAPIA FARMACOLÓGICA EN TRICOLOGÍA
- a. Tratamiento antiandrogénico
  - b. Tratamiento inmunomodulador
  - c. Terapias intervencionistas
4. ALOPECIA ANDROGÉNICA MASCULINA
- a. Diagnóstico y manejo clínico
  - b. Tratamiento y seguimiento
5. ALOPECIA ANDROGÉNICA FEMENINA
- a. Diagnóstico y manejo clínico
  - b. Tratamiento y seguimiento
6. EFLUVIOS
- a. Efluvio telógeno agudo
  - b. Efluvio telógeno crónico
7. ALOPECIA AREATA
- a. Alopecia areata en placas
  - b. Alopecia areata multifocal
  - c. Alopecia areata total y universal

- d. Tratamiento y seguimiento
- e. Nuevas líneas de investigación
- 8. ALOPECIA FRONTAL FIBROSANTE
  - a. Epidemiología y etiopatogenia
  - b. Diagnóstico y manejo clínico
  - c. Tratamiento y seguimiento
- 9. LIQUEN PLANO PILAR Y FAPD
  - a. Epidemiología y etiopatogenia
  - b. Diagnóstico y manejo clínico
  - c. Tratamiento y seguimiento
- 10. FOLICULITIS DECALVANTE
  - a. Epidemiología y etiopatogenia
  - b. Diagnóstico y manejo clínico
  - c. Tratamiento y seguimiento
  - d. Nuevas líneas de investigación
- 11. OTRAS ALOPECIAS
  - a. Lupus discoide
  - b. Celulitis disecante
  - c. Alopecia cicatricial central centrífuga
  - d. Alopecia traccional
- 12. TRICOLOGÍA PEDIÁTRICA
  - a. Distrofias congénitas
  - b. Alopecia areata
  - c. Tricotilomanía
  - d. Pediculosis e infestaciones
- 13. AFECCIONES DEL CUERO CABELLUDO
  - a. Dermatitis seborreica
  - b. Psoriasis
  - c. Dermatitis atópica y liquen simple crónico
  - d. Tiña e infecciones
- 14. REACCIONES CAPILARES A FÁRMACOS Y ALOPECIA EN EL PACIENTE ONCOLÓGICO.
  - a. Alopecia por quimioterapia
  - b. Alopecia permanente por quimioterapia
  - c. Alopecia por hormonoterapia
  - d. Alteraciones capilares por terapias dirigidas
- 15. TRASPLANTE CAPILAR
  - a. Técnica FUT
  - b. Técnica FUE
  - c. Selección de paciente varón
  - d. Selección de paciente femenino
  - e. Material y personal
- 16. TERAPIAS EMERGENTES
  - a. Láser de baja potencia
  - b. Activadores de la vía Wnt
  - c. Prostaglandinas
  - d. Células madre
- 17. PROCEDIMIENTOS EN TRICOLOGÍA:
  - a. MESOTERAPIA CON DUTASTERIDA
  - b. Bioestimulación con plasma rico en plaquetas
  - c. INFILTRACIONES CON TRIGÓN
  - d. INMUNOTERAPIA CON DIFENCIPRONA
- 18. COSMÉTICA CAPILAR
  - a. Microfibras capilares y sistemas de camuflaje
  - b. Micropigmentación y microblading
  - c. Sistemas FAS
- 19. CÓMO REALIZAR UN ESTUDIO CIENTÍFICO EN TRICOLOGÍA
  - a. Búsqueda bibliográfica
  - b. Uso de Mendeley

- c. Diseño y planificación de estudios multicéntricos  
d. Redacción de artículos
20. GESTIÓN Y MARKETING DE UNA UNIDAD DE TRICOLOGÍA
- a. Planificación económica  
b. Uso de redes sociales

## EVALUACIÓN

Examen tipo test.

## BIBLIOGRAFÍA

1. Gupta AK, Charrette A. Topical minoxidil: Systematic review and meta-analysis of its efficacy in androgenetic alopecia. *Skinmed*. 2015;13:185---9
2. Van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. *Cochrane Database Syst Rev*. 2012;5:CD007628
3. Kanti V, Hillmann K, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: A 104-week open-label clinical trial. *J Eur Acad Dermatol Venereol*. 2016;30:1183---9
4. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. *J Am Acad Dermatol*. 2011;65:1126---34,
5. Mali N, Darandale S, Vavia P. Niosomes as a vesicular Carrier for topical administration of minoxidil: Formulation and in vitro assessment. *Drug Deliv Transl Res*. 2013;3:587---92.
6. Yang X, Thai KE. Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil. *Australas J Dermatol*. 2015
7. Sinclair R. Treatment of monilethrix with oral minoxidil. *JAAD Case Rep*. 2016;2:212---5.
8. Liu L, Zhao S, Li F, Li E, Kang R, Luo L, et al. Effect of 5- $\alpha$ -reductase inhibitors on sexual function: A meta-analysis and systematic review of randomized controlled trials. *J Sex Med*. 2016.
9. Seale LR, Eglini AN, McMichael AJ. Side effects related to 5- $\alpha$ -reductase inhibitor treatment of hair loss in women: A review. *J Drugs Dermatol*. 2016;15:414---9
10. Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, et al. Finasteride concentrations and prostate cancer risk: Results from the Prostate Cancer Prevention Trial. *PLoS One*. 2015;10:e0126672
11. Duijnhoven RG, Straus SMJM, Souverein PC, de Boer A, Bosch JLHR, Hoes AW, et al. Long-term use of 5- $\alpha$ -reductase inhibitors and the risk of male breast cancer. *Cancer Causes Control*. 2014;25:1577---82
12. Gupta AK, Charrette A. The efficacy and safety of 5- $\alpha$ -reductase inhibitors in androgenetic alopecia: A network meta-analysis and benefit-risk assessment of finasteride and dutasteride. *J Dermatolog Treat*. 2014;25:156---61
13. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. *Indian J Dermatol Venereol Leprol*. 2014;80:521---5
14. Shanshanwal SJS, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. *Indian J Dermatol Venereol Leprol*. 2017;83:47---54
15. Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. *Int J Dermatol*. 2014;53:1351---7
16. Gubelin Harcha W, Barboza Martínez J, Tsai T-F, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. *J Am Acad Dermatol*. 2014;70:489---98.e3
17. Tsunemi Y, Irisawa R, Yoshiie H, Brotherton B, Ito H, Tsuboi R, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. *J Dermatol*. 2016;43:1051---8
18. Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, et al. Meso-therapy using dutasteride-containing preparation in treatment of female pattern hair loss: Photographic, morphometric and ultrastructural evaluation. *J Eur Acad Dermatol Venereol*. 2013;27:686---93

19. Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri, R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. *Int J Clin Pharmacol Ther.* 2016;54:19---27
20. Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: Pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. *Int J Clin Pharmacol Ther.* 2014;52:842---9
21. Choi YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F2<sub>α</sub> analogs: Beyond the eyelashes. *J Am Acad Dermatol.* 2015;72:712---6
22. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels. N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. *J Am Acad Dermatol.* 2012;66:794---800
23. Nieves A, Garza LA. Does prostaglandin D2 hold the cure to male pattern baldness? *Exp Dermatol.* 2014;23:224---7
24. Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. *Expert Opin Investig Drugs.* 2013;22:573---89
25. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. *Sci Transl Med.* 2012;4
26. Keaney T. Emerging therapies for androgenetic alopecia. *J Drugs. Dermatol.* 2015;14:1036---40
27. Zarei M, Wikramanayake TC, Falto-Aizpurua L, Schachner LA, Jimenez JJ. Low level laser therapy and hair regrowth: An evidence-based review. *Lasers Med Sci.* 2016;31:363---71
28. Jimenez JJ, Wikramanayake TC, Bergfeld W, Hordinsky M, Hickman, JG, Hamblin MR, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: A multicenter, randomized, sham device-controlled, double-blind study. *Am J Clin Dermatol.* 2014;15:115---27
29. Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Lowlevel laser (light) therapy (LLLT) for treatment of hair loss. *Lasers Surg Med.* 2014;46:144---51
30. Kim H, Choi JW, Kim JY, Shin JW, Lee S-J, Huh C-H. Lowlevel light therapy for androgenetic alopecia: A 24-week, randomized, double-blind, sham device-controlled multicenter trial. *Dermatol Surg.* 2013;39:1177---83
31. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: A pilot study. *Int J Trichology.* 2013;5:6---11
32. Dhurat R, Mathapati S. Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. *Indian J Dermatol.* 2015;60:260---3
33. Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V, et al. The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. *Stem Cells Transl Med.* 2015;4:1317---23
34. Gupta AK, Carviel JL. Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. *J Dermatolog Treat.* 2016;1---4
35. Alves R, Grimalt R. Randomized placebo-controlled, doubleblind half-head study to assess the efficacy of plateletrich plasma on the treatment of androgenetic alopecia. *Dermatol Surg.* 2016;42:491---7
36. Tosti A, Zaiac MN, Canazza A, Sanchis-Gomar F, Pareja-Galeano H, Alis R, et al. Topical application of the Wnt/-catenin activator methyl vanillate increases hair count and hair mass index in women with androgenetic alopecia. *J Cosmet Dermatol.* 2016
37. Jo SJ, Shin H, Park YW, Paik SH, Park WS, Jeong YS, et al. Topical valproic acid increases the hair count in male patients with androgenetic alopecia: A randomized, comparative, clinical feasibility study using phototrichogram analysis. *J Dermatol.* 2014;41:285---91
38. Yazici Y. Safety and efficacy of a topical treatment (SM04554) for androgenetic alopecia (AGA): Results from a phase 1 Trial. *J Am Acad Dermatol.* 2016;74:AB138
39. Deng Z, Lei X, Zhang X, Zhang H, Liu S, Chen Q, et al. mTOR signaling promotes stem cell activation via counterbalancing BMP-mediated suppression during hair regeneration. *J Mol Cell Biol.* 2015;7:62---72
40. Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. *Sci Adv.* 2015;1:e1500973
41. Carrasco E, Calvo MI, Blázquez-Castro A, Vecchio D, Zamarrón A, de Almeida IJD, et al. Photoactivation of ROS production in situ transiently activates cell proliferation in mouse skin and in the hair follicle stem cell niche promoting hair growth and wound healing. *J Invest Dermatol.* 2015;135:2611---22
42. McElwee KJ, Kissling S, Wenzel E, Huth A, Hoffmann R. Cultured peribulbar dermal sheath cells can induce hair follicle development and contribute to the dermal sheath and dermal papilla. *J Invest Dermatol.* 2003;121:1267---75,

43. Shin H, Ryu HH, Kwon O, Park B-S, Jo SJ. Clinical use of conditioned media of adipose issue-derived stem cells in female pattern hair loss: A retrospective case series study. *Int J Dermatol.* 2015;54:730---5
44. Fukuoka H, Suga H. Hair regeneration treatment using adipose-derived stem cell conditioned medium: Follow-up with trichograms. *Eplasty.* 2015;15:e10
45. Zhang P, Kling RE, Ravuri SK, Kokai LE, Rubin JP, Chai J-K, et al. A review of adipocyte lineage cells and dermal papilla cells in hair follicle regeneration. *J Tissue Eng.* 2014;5
46. Lamb RC, Young D, Holmes S. Retrospective review of diphencyprone in the treatment of alopecia areata. *Clin Exp Dermatol.*
47. Shreberk-Hassidim R, Ramot Y, Gilula Z, Zlotogorski A. A systematic review of pulse steroid therapy for alopecia areata. *J Am Acad Dermatol.* 2016;74:372e1---4e5
48. Vaño Galván S, Hermosa-Gelbard Á, Sánchez-Neila N, Miguel Gómez L, Saceda-Corralo D, Rodrigues-Barata R, et al. Pulse corticosteroid therapy with oral dexamethasone for the treatment of adult alopecia totalis and universalis. *J Am Acad Dermatol.* 2016;74:1005---7
49. Lattouf C, Jimenez JJ, Tosti A, Miteva M, Wikramanayake TC, Kittles C, et al. Treatment of alopecia areata with simvastatin ezetimibe. *J Am Acad Dermatol.* 2015;72:359---61
50. Loi C, Starace M, Piraccini BM. Alopecia areata (AA) and treatment with simvastatin/ezetimibe: Experience of 20 patients. *J Am Acad Dermatol.* 2016;74:e99---100
51. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. *Nat Med.* 2014;20:1043---9
52. Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. *JAMA Dermatol.* 2016;152:490---1
53. Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. *EBioMedicine.* 2015;2:351---5
54. Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). *J Am Acad Dermatol.* 2016;74:370--1
55. Jabbari A, Nguyen N, Cerise JE, Ulerio G, de Jong A, Clynes R, et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. *Exp Dermatol.* 2016
56. Mrowietz U, Gerdes S, Gläser R, Schröder O. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. *Acta Derm Venereol.* 2016
57. Gupta AK, Carviel JL, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. *J Eur Acad Dermatol Venereol.* 2016
58. Anzengruber F, Maul J-T, Kamarachev J, Trüeb RM, French, LE, Navarini AA. Transient efficacy of tofacitinib in alopecia areata universalis. *Case Rep Dermatol.* 2016;8:102---6
59. Vañoó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, Arias-Santiago S, Rodrigues-Barata AR, Garnacho-Saucedo G, et al. Frontal fibrosing alopecia: A multicenter review of 355 patients. *J Am Acad Dermatol.* 2014;70:670---8
60. Ladizinski B, Bazakas A, Selim MA, Olsen EA. Frontal fibrosing alopecia: A retrospective review of 19 patients seen at Duke University. *J Am Acad Dermatol.* 2013;68:749---55,
61. Vañoó-Galván S, Saceda-Corral D, Alonso-Castro L, Urech M, Espada J. Antiandrogenic drugs, a therapeutic option for frontal fibrosing alopecia patients. *J Am Acad Dermatol.* 2016;74:e77
62. Harries MJ, Messenger A. Treatment of frontal fibrosing alopecia and lichen planopilaris. *J Eur Acad Dermatol Venereol.* 2014;28:1404---5
63. Martínez-Pérez M, Churruca-Grijelmo M. Frontal fibrosing alopecia: An update on epidemiology and treatment. *Actas Dermosifiliogr.* 2015;106:757---8
64. Donovan JC. Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. *JAAD Case Rep.* 2015;1:353---5
65. Tziotziou C, Fenton DA, Stefanato CM, McGrath JA. Finasteride is of uncertain utility in treating frontal fibrosing alopecia. *J Am Acad Dermatol.* 2016;74:e73---4
66. Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. *J Invest Dermatol.* 2009;129:1243---57
67. Spring P, Spanou Z, de Viragh PA. Lichen planopilaris treated by the peroxisome proliferator activated receptor-agonist pioglitazone: Lack of lasting improvement or cure in the majority of patients. *J Am Acad Dermatol.* 2013;69:830---2

68. Mesinkovska NA, Tellez A, Dawes D, Piliang M, Bergfeld W. The use of oral pioglitazone in the treatment of lichen planopilaris. *J Am Acad Dermatol.* 2015;72:355---6
69. Mirmirani P, Karnik P. Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. *Arch Dermatol.* 2009;145:1363---6
70. Baibergenova A, Walsh S. Use of pioglitazone in patients with lichen planopilaris. *J Cutan Med Surg.* 2012;16:97---100
71. Márquez-García A, Camacho FM. Tratamiento de la alopecia frontal fibrosante: pioglitazonas. *Monogr Dermatol.* 2016;29:66---76.
72. Vañó-Galván S, Molina-Ruiz AM, Fernández-Crehuet P, Rodrigues-Barata AR, Arias-Santiago S, Serrano-Falcón C, et al. Folliculitis decalvans: A multicentre review of 82 patients. *J Eur. Acad Dermatol Venereol.* 2015;29:1750---7
73. Miguel-Gomez L, Vano-Galvan S, Perez-Garcia B, Carrillo-Gijon R, Jaen-Olasolo P. Treatment of folliculitis decalvans with photodynamic therapy: Results in 10 patients. *J Am. Acad Dermatol.* 2015;72:1085---7
74. Burillo-Martinez S, Maroñas-Jimenez L, Palencia-Pérez SI, Vanaclocha-Sebastián F, López-Gómez S. Failure of photodynamic therapy (PDT) in 3 patients with folliculitis decalvans. *J Am Acad Dermatol.* 2016;74:e69--70
75. Avram MR, Watkins SA. Robotic follicular unit extraction in hair transplantation. *Dermatol Surg.* 2014;40:1319---27
76. Gho CG, Neumann HAM. Advances in hair transplantation: Longitudinal partial follicular unit transplantation. *Curr Probl Dermatol.* 2015;47:150---7
77. Vañó-Galván S, Camacho F. Novedades terapéuticas en tricología. *Actas Dermosifiliogr.* 2016.

## GUÍA DOCENTE

Año académico	2019-2020	
Estudio	Experto en Tricología médico-estética avanzada (EÑ13)	
Nombre de la asignatura	PRÁCTICA CLÍNICA EN TRICOLOGÍA MÉDICO-ESTÉTICA	
Carácter (Obligatoria/Optativa)	OB	
Créditos (1 ECTS=25 horas)	7	
Modalidad (elegir una opción)		Presencial
	x	Semipresencial
		On-line
Profesor responsable	Sergio Vañó Galván	
Idioma en el que se imparte	Español	

### DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)

Número de horas presenciales/on-line asistencia profesor	49
Número de horas de trabajo personal del estudiante	126
Total horas	175

### CONTENIDOS (Temario)

Asistencia a consulta clínica de tricología, observación de realización de técnicas médico-estéticas avanzadas, realización de técnicas bajo supervisión

### EVALUACIÓN

Evaluación individual por parte del tutor asignado durante las prácticas clínicas.

### BIBLIOGRAFÍA

1. Gupta AK, Charrette A. Topical minoxidil: Systematic review and meta-analysis of its efficacy in androgenetic alopecia. *Skinmed*. 2015;13:185---9
2. Van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. *Cochrane Database Syst Rev*. 2012;5:CD007628
3. Kanti V, Hillmann K, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: A 104-week open-label clinical trial. *J Eur Acad Dermatol Venereol*. 2016;30:1183---9
4. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. *J Am Acad Dermatol*. 2011;65:1126---34,
5. Mali N, Darandale S, Vavia P. Niosomes as a vesicular Carrier for topical administration of minoxidil: Formulation and in vitro assessment. *Drug Deliv Transl Res*. 2013;3:587---92.
6. Yang X, Thai KE. Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil. *Australas J Dermatol*. 2015
7. Sinclair R. Treatment of monilethrix with oral minoxidil. *JAAD Case Rep*. 2016;2:212---5.



8. Liu L, Zhao S, Li F, Li E, Kang R, Luo L, et al. Effect of 5 $\alpha$ -reductase inhibitors on sexual function: A meta-analysis and systematic review of randomized controlled trials. *J Sex Med.* 2016.
9. Seale LR, Eglini AN, McMichael AJ. Side effects related to 5 $\alpha$ -reductase inhibitor treatment of hair loss in women: A review. *J Drugs Dermatol.* 2016;15:414---9
10. Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, et al. Finasteride concentrations and prostate cancer risk: Results from the Prostate Cancer Prevention Trial. *PLoS One.* 2015;10:e0126672
11. Duijnhoven RG, Straus SMJM, Souverein PC, de Boer A, Bosch JLHR, Hoes AW, et al. Long-term use of 5 $\alpha$ -reductase inhibitors and the risk of male breast cancer. *Cancer Causes Control.* 2014;25:1577---82
12. Gupta AK, Charrette A. The efficacy and safety of 5 $\alpha$ -reductase inhibitors in androgenetic alopecia: A network meta-analysis and benefit-risk assessment of finasteride and dutasteride. *J Dermatolog Treat.* 2014;25:156---61
13. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. *Indian J Dermatol Venereol Leprol.* 2014;80:521---5
14. Shanshanwal SJS, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. *Indian J Dermatol Venereol Leprol.* 2017;83:47---54
15. Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. *Int J Dermatol.* 2014;53:1351---7
16. Gubelin Harcha W, Barboza Martínez J, Tsai T-F, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. *J Am Acad Dermatol.* 2014;70:489---98.e3
17. Tsunemi Y, Irisawa R, Yoshiie H, Brotherton B, Ito H, Tsuboi R, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. *J Dermatol.* 2016;43:1051---8
18. Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: Photographic, morphometric and ultrastructural evaluation. *J Eur Acad Dermatol Venereol.* 2013;27:686---93
19. Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri, R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. *Int J Clin Pharmacol Ther.* 2016;54:19---27
20. Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: Pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. *Int J Clin Pharmacol Ther.* 2014;52:842---9
21. Choi YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F<sub>2</sub> analogs: Beyond the eyelashes. *J Am Acad Dermatol.* 2015;72:712---6
22. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels. N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. *J Am Acad Dermatol.* 2012;66:794---800
23. Nieves A, Garza LA. Does prostaglandin D2 hold the cure to male pattern baldness? *Exp Dermatol.* 2014;23:224---7
24. Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. *Expert Opin Investig Drugs.* 2013;22:573---89
25. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. *Sci Transl Med.* 2012;4
26. Keaney T. Emerging therapies for androgenetic alopecia. *J Drugs. Dermatol.* 2015;14:1036---40
27. Zarei M, Wikramanayake TC, Falto-Aizpurua L, Schachner LA, Jimenez JJ. Low level laser therapy and hair regrowth: An evidence-based review. *Lasers Med Sci.* 2016;31:363---71
28. Jimenez JJ, Wikramanayake TC, Bergfeld W, Hordinsky M, Hickman, JG, Hamblin MR, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: A multicenter, randomized, sham device-controlled, double-blind study. *Am J Clin Dermatol.* 2014;15:115---27
29. Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Lowlevel laser (light) therapy (LLLT) for treatment of hair loss. *Lasers Surg Med.* 2014;46:144---51

30. Kim H, Choi JW, Kim JY, Shin JW, Lee S-J, Huh C-H. Lowlevel light therapy for androgenetic alopecia: A 24-week, randomized, double-blind, sham device-controlled multicenter trial. *Dermatol Surg.* 2013;39:1177---83
31. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: A pilot study. *Int J Trichology.* 2013;5:6---11
32. Dhurat R, Mathapati S. Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. *Indian J Dermatol.* 2015;60:260---3
33. Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V, et al. The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. *Stem Cells Transl Med.* 2015;4:1317---23
34. Gupta AK, Carviel JL. Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. *J Dermatolog Treat.* 2016:1---4
35. Alves R, Grimalt R. Randomized placebo-controlled, doubleblind half-head study to assess the efficacy of plateletrich plasma on the treatment of androgenetic alopecia. *Dermatol Surg.* 2016;42:491---7
36. Tosti A, Zaiac MN, Canazza A, Sanchis-Gomar F, Pareja-Galeano H, Alis R, et al. Topical application of the Wnt/-catenin activator methyl vanillate increases hair count and hair mass index in women with androgenetic alopecia. *J Cosmet Dermatol.* 2016
37. Jo SJ, Shin H, Park YW, Paik SH, Park WS, Jeong YS, et al. Topical valproic acid increases the hair count in male patients with androgenetic alopecia: A randomized, comparative, clinical feasibility study using phototrichogram analysis. *J Dermatol.* 2014;41:285---91
38. Yazici Y. Safety and efficacy of a topical treatment (SM04554) for androgenetic alopecia (AGA): Results from a phase 1 Trial. *J Am Acad Dermatol.* 2016;74:AB138
39. Deng Z, Lei X, Zhang X, Zhang H, Liu S, Chen Q, et al. mTOR signaling promotes stem cell activation via counterbalancing BMP-mediated suppression during hair regeneration. *J Mol Cell Biol.* 2015;7:62---72
40. Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. *Sci Adv.* 2015;1:e1500973
41. Carrasco E, Calvo MI, Blázquez-Castro A, Vecchio D, Zamarrón A, de Almeida IJD, et al. Photoactivation of ROS production in situ transiently activates cell proliferation in mouse skin and in the hair follicle stem cell niche promoting hair growth and wound healing. *J Invest Dermatol.* 2015;135:2611---22
42. McElwee KJ, Kissling S, Wenzel E, Huth A, Hoffmann R. Cultured peribulbar dermal sheath cells can induce hair follicle development and contribute to the dermal sheath and dermal papilla. *J Invest Dermatol.* 2003;121:1267---75,
43. Shin H, Ryu HH, Kwon O, Park B-S, Jo SJ. Clinical use of conditioned media of adipose issue-derived stem cells in female pattern hair loss: A retrospective case series study. *Int J Dermatol.* 2015;54:730---5
44. Fukuoka H, Suga H. Hair regeneration treatment using adipose-derived stem cell conditioned medium: Follow-up with trichograms. *Eplasty.* 2015;15:e10
45. Zhang P, Kling RE, Ravuri SK, Kokai LE, Rubin JP, Chai J-K, et al. A review of adipocyte lineage cells and dermal papilla cells in hair follicle regeneration. *J Tissue Eng.* 2014;5
46. Lamb RC, Young D, Holmes S. Retrospective review of diphencyprone in the treatment of alopecia areata. *Clin Exp Dermatol.*
47. Shreberk-Hassidim R, Ramot Y, Gilula Z, Zlotogorski A. A systematic review of pulse steroid therapy for alopecia areata. *J Am Acad Dermatol.* 2016;74:372e1---4e5
48. Vaño Galván S, Hermosa-Gelbard Á, Sánchez-Neila N, Miguel Gómez L, Saceda-Corralo D, Rodrigues-Barata R, et al. Pulse corticosteroid therapy with oral dexamethasone for the treatment of adult alopecia totalis and universalis. *J Am Acad Dermatol.* 2016;74:1005---7
49. Lattouf C, Jimenez JJ, Tosti A, Miteva M, Wikramanayake TC, Kittles C, et al. Treatment of alopecia areata with simvastatin ezetimibe. *J Am Acad Dermatol.* 2015;72:359---61
50. Loi C, Starace M, Piraccini BM. Alopecia areata (AA) and treatment with simvastatin/ezetimibe: Experience of 20 patients. *J Am Acad Dermatol.* 2016;74:e99---100
51. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. *Nat Med.* 2014;20:1043---9
52. Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. *JAMA Dermatol.* 2016;152:490---1
53. Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. *EBioMedicine.* 2015;2:351---5
54. Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). *J Am Acad Dermatol.* 2016;74:370--1

55. Jabbari A, Nguyen N, Cerise JE, Ulerio G, de Jong A, Clynes R, et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. *Exp Dermatol*. 2016
56. Mrowietz U, Gerdes S, Gläser R, Schröder O. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. *Acta Derm Venereol*. 2016
57. Gupta AK, Carviel JL, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. *J Eur Acad Dermatol Venereol*. 2016
58. Anzengruber F, Maul J-T, Kamarachev J, Trüeb RM, French, LE, Navarini AA. Transient efficacy of tofacitinib in alopecia areata universalis. *Case Rep Dermatol*. 2016;8:102---6
59. Vañoó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, Arias-Santiago S, Rodrigues-Barata AR, Garnacho-Saucedo G, et al. Frontal fibrosing alopecia: A multicenter review of 355 patients. *J Am Acad Dermatol*. 2014;70:670---8
60. Ladizinski B, Bazakas A, Selim MA, Olsen EA. Frontal fibrosing alopecia: A retrospective review of 19 patients seen at Duke University. *J Am Acad Dermatol*. 2013;68:749---55,
61. Vañoó-Galván S, Saceda-Corral D, Alonso-Castro L, Urech M, Espada J. Antiandrogenic drugs, a therapeutic option for frontal fibrosing alopecia patients. *J Am Acad Dermatol*. 2016;74:e77
62. Harries MJ, Messenger A. Treatment of frontal fibrosing alopecia and lichen planopilaris. *J Eur Acad Dermatol Venereol*. 2014;28:1404---5
63. Martínez-Pérez M, Churruca-Grijelmo M. Frontal fibrosing alopecia: An update on epidemiology and treatment. *Actas Dermosifiliogr*. 2015;106:757---8
64. Donovan JC. Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. *JAAD Case Rep*. 2015;1:353---5
65. Tziotzios C, Fenton DA, Stefanato CM, McGrath JA. Finasteride is of uncertain utility in treating frontal fibrosing alopecia. *J Am Acad Dermatol*. 2016;74:e73---4
66. Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. *J Invest Dermatol*. 2009;129:1243---57
67. Spring P, Spanou Z, de Viragh PA. Lichen planopilaris treated by the peroxisome proliferator activated receptor-agonist pioglitazone: Lack of lasting improvement or cure in the majority of patients. *J Am Acad Dermatol*. 2013;69:830---2
68. Mesinkovska NA, Tellez A, Dawes D, Piliang M, Bergfeld W. The use of oral pioglitazone in the treatment of lichen planopilaris. *J Am Acad Dermatol*. 2015;72:355---6
69. Mirmirani P, Karnik P. Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. *Arch Dermatol*. 2009;145:1363---6
70. Baibergenova A, Walsh S. Use of pioglitazone in patients with lichen planopilaris. *J Cutan Med Surg*. 2012;16:97---100
71. Márquez-García A, Camacho FM. Tratamiento de la alopecia frontal fibrosante: pioglitazonas. *Monogr Dermatol*. 2016;29:66---76.
72. Vañoó-Galván S, Molina-Ruiz AM, Fernández-Crehuet P, Rodrigues-Barata AR, Arias-Santiago S, Serrano-Falcón C, et al. Folliculitis decalvans: A multicentre review of 82 patients. *J Eur. Acad Dermatol Venereol*. 2015;29:1750---7
73. Miguel-Gomez L, Vano-Galvan S, Perez-Garcia B, Carrillo-Gijon R, Jaen-Olasolo P. Treatment of folliculitis decalvans with photodynamic therapy: Results in 10 patients. *J Am. Acad Dermatol*. 2015;72:1085---7
74. Burillo-Martinez S, Maroñas-Jimenez L, Palencia-Pérez SI, Vanaclocha-Sebastián F, López-Gómez S. Failure of photodynamic therapy (PDT) in 3 patients with folliculitis decalvans. *J Am Acad Dermatol*. 2016;74:e69--70
75. Avram MR, Watkins SA. Robotic follicular unit extraction in hair transplantation. *Dermatol Surg*. 2014;40:1319---27
76. Gho CG, Neumann HAM. Advances in hair transplantation: Longitudinal partial follicular unit transplantation. *Curr Probl Dermatol*. 2015;47:150---7
77. Vañoó-Galván S, Camacho F. Novedades terapéuticas en tricología. *Actas Dermosifiliogr*. 2016.

## GUÍA DOCENTE

Año académico	2019-2020	
Estudio	Experto en Tricología médico-estética avanzada (EÑ13)	
Nombre de la asignatura	TRABAJO DE INVESTIGACIÓN DE FIN DE CURSO	
Carácter (Obligatoria/Optativa)	OB	
Créditos (1 ECTS=25 horas)	10	
Modalidad (elegir una opción)		Presencial
	x	Semipresencial
		On-line
Profesor responsable	Sergio Vañó	
Idioma en el que se imparte	Español	

### DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)

Número de horas presenciales/on-line asistencia profesor	70
Número de horas de trabajo personal del estudiante	180
Total horas	250

### CONTENIDOS (Temario)

Realización del trabajo de fin de curso consiste en una revisión bibliográfica exhaustiva de un tema concreto o bien un proyecto de investigación planteado por el alumno o el profesorado.

### EVALUACIÓN

Los criterios de evaluación del TFM son:

- El contenido se ajusta al tema propuesto.
- El contenido está bien escrito gramaticalmente y bien desarrollado.
- En la discusión hace una buena reflexión y desarrollo del tema de forma original.
- Se aporta bibliografía significativa.
- Las conclusiones son personales del alumno.
- Aporta información actualizada.
- Amplía el conocimiento desarrollado en esa área hasta la fecha.

### BIBLIOGRAFÍA

Se aportará según la temática del proyecto a desarrollar.